GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sierra Oncology Inc (NAS:SRRA) » Definitions » Insider Ownership

Sierra Oncology (Sierra Oncology) Insider Ownership : 2.05 % (As of May. 23, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Sierra Oncology Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sierra Oncology's insider ownership is 2.05%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sierra Oncology's Institutional Ownership is 12.13%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sierra Oncology's Float Percentage Of Total Shares Outstanding is 59.98%.


Sierra Oncology Insider Ownership Historical Data

The historical data trend for Sierra Oncology's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sierra Oncology Insider Ownership Chart

Sierra Oncology Historical Data

The historical data trend for Sierra Oncology can be seen below:

2021-07-31 2021-08-31 2021-09-30 2021-10-31 2021-11-30 2021-12-31 2022-01-31 2022-02-28 2022-03-31 2022-05-31
Insider Ownership 3.95 3.88 3.88 3.88 3.33 3.33 2.55 2.40 2.12 2.05

Sierra Oncology Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Sierra Oncology (Sierra Oncology) Business Description

Traded in Other Exchanges
N/A
Address
1820 Gateway Drive, Suite 110, San Mateo, USA, 94404
Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.
Executives
Vivo Opportunity Fund Holdings, L.p. director, 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
William D. Turner officer: Chief Reg & Tech Ops Officer C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Mary Christina Thomson officer: General Counsel C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Joshua Richardson director, 10 percent owner C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Longitude Prime Fund, L.p. 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Gaurav Aggarwal director, 10 percent owner C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Vivo Opportunity Fund, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Andrew Sinclair director C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Craig A Collard director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Georgia Erbez director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Christy J. Oliger director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459